{"success":true,"data":{"pressRelease":{"id":"147039","rtpr_id":"nGNX80RqmC-20260918","ticker":"ETRA","exchange":"NASDAQ","all_tickers":["ETRA"],"title":"Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering","author":"Globe Newswire","published_at":"2026-09-18T00:30:00.097Z","article_body":"SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra\nTherapeutics, Inc., a late clinical-stage biopharmaceutical company focused on\npioneering a new class of precision medicines for the treatment of\nimmune-mediated diseases and cancer, today announced the pricing of its\nupsized initial public offering of 23,333,334 shares of common stock at a\nprice to the public of $15.00 per share. The gross proceeds to Electra from\nthe offering, before deducting underwriting discounts and commissions and\nestimated offering expenses payable by Electra, are expected to be\napproximately $350.0 million. In addition, Electra has granted the\nunderwriters a 30-day option to purchase up to an additional 3,500,000 shares\nof common stock at the public offering price, less underwriting discounts and\ncommissions. All of the shares of common stock are being offered by Electra.\n\nThe shares are expected to begin trading on The Nasdaq Global Select Market on\nSeptember 18, 2026, under the ticker symbol “ETRA.” The offering is\nexpected to close on September 21, 2026, subject to the satisfaction of\ncustomary closing conditions.\nJefferies, TD Cowen, Evercore ISI and Cantor are acting as joint book-running\nmanagers for the offering.\n\nRegistration statements relating to these securities have been filed with the\nU.S. Securities and Exchange Commission (SEC) and became effective on\nSeptember 17, 2026. Copies of the registration statements can be accessed\nthrough the SEC’s website at www.sec.gov. This offering is being made only\nby means of a prospectus forming part of the registration statements relating\nto these securities. When available, copies of the final prospectus relating\nto the initial public offering may be obtained from: Jefferies LLC, Attention:\nEquity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York\n10022, by telephone at (877) 821-7388 or by email at\nProspectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge\nFinancial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email\nat TDManualrequest@broadridge.com; Evercore Group L.L.C., 55 East 52nd Street,\n35th Floor, New York, New York 10055, Attention: Equity Capital Markets, or by\nemail at ecm.prospectus@evercore.com or by telephone at (888) 474-0200; or\nCantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 East 59th\nStreet, 6th Floor, New York, New York 10022, or by email at\nprospectus@cantor.com. \nThis press release does not constitute an offer to sell, or the solicitation\nof an offer to buy these securities, nor shall there be any sale of these\nsecurities in any state or jurisdiction in which such offer, solicitation or\nsale would be unlawful prior to the registration or qualification under the\nsecurities laws of any such state or jurisdiction. Any offers, solicitations\nof offers to buy, or any sales of securities will be made in accordance with\nthe registration requirements of the Securities Act of 1933, as amended.\n\nAbout Electra Therapeutics\n\nElectra Therapeutics is a late clinical-stage biopharmaceutical company\nfocused on pioneering a new class of precision medicines for the treatment of\nimmune-mediated diseases and cancer. The company’s novel approach targets\nsignal regulatory proteins (SIRP), a family of cell surface receptors whose\nexpression is restricted to specific immune cell populations and increases\nupon activation, to enable selective depletion of disease-driving cells while\npreserving normal immune function. The company’s lead product candidate,\nipsoprubart (ELA026), is a novel pan-SIRP monoclonal antibody currently in a\nglobal registrational program for secondary hemophagocytic lymphohistiocytosis\n(sHLH), a severe hyperinflammatory syndrome for which there are no broadly\napproved therapies and survival has remained consistently poor over the past\ntwo decades. Ipsoprubart is also being evaluated in a Phase 1 clinical trial\nin patients with relapsed/refractory T-cell and natural-killer cell\nmalignancies. ELA822, the company’s second clinical-stage product candidate,\nis a novel SIRPγ-specific antibody being developed for a broad range of\nchronic T cell-mediated immune and inflammatory diseases.\n\nContacts:\n\nInvestor Contact:\nMonique Allaire, THRUST\nmonique@thrustsc.com\n\nMedia Contact:\nSara Sutton, THRUST\nsarah@thrustsc.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/fd8fd901-e478-4b5f-91b6-0bdce351f95f)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX80RqmC-20260918","title":"Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering","author":"Globe Newswire","ticker":"ETRA","created":"2026-09-18T00:30:00.097Z","tickers":["ETRA"],"exchange":"NASDAQ","article_body":"SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra\nTherapeutics, Inc., a late clinical-stage biopharmaceutical company focused on\npioneering a new class of precision medicines for the treatment of\nimmune-mediated diseases and cancer, today announced the pricing of its\nupsized initial public offering of 23,333,334 shares of common stock at a\nprice to the public of $15.00 per share. The gross proceeds to Electra from\nthe offering, before deducting underwriting discounts and commissions and\nestimated offering expenses payable by Electra, are expected to be\napproximately $350.0 million. In addition, Electra has granted the\nunderwriters a 30-day option to purchase up to an additional 3,500,000 shares\nof common stock at the public offering price, less underwriting discounts and\ncommissions. All of the shares of common stock are being offered by Electra.\n\nThe shares are expected to begin trading on The Nasdaq Global Select Market on\nSeptember 18, 2026, under the ticker symbol “ETRA.” The offering is\nexpected to close on September 21, 2026, subject to the satisfaction of\ncustomary closing conditions.\nJefferies, TD Cowen, Evercore ISI and Cantor are acting as joint book-running\nmanagers for the offering.\n\nRegistration statements relating to these securities have been filed with the\nU.S. Securities and Exchange Commission (SEC) and became effective on\nSeptember 17, 2026. Copies of the registration statements can be accessed\nthrough the SEC’s website at www.sec.gov. This offering is being made only\nby means of a prospectus forming part of the registration statements relating\nto these securities. When available, copies of the final prospectus relating\nto the initial public offering may be obtained from: Jefferies LLC, Attention:\nEquity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York\n10022, by telephone at (877) 821-7388 or by email at\nProspectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge\nFinancial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email\nat TDManualrequest@broadridge.com; Evercore Group L.L.C., 55 East 52nd Street,\n35th Floor, New York, New York 10055, Attention: Equity Capital Markets, or by\nemail at ecm.prospectus@evercore.com or by telephone at (888) 474-0200; or\nCantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 East 59th\nStreet, 6th Floor, New York, New York 10022, or by email at\nprospectus@cantor.com. \nThis press release does not constitute an offer to sell, or the solicitation\nof an offer to buy these securities, nor shall there be any sale of these\nsecurities in any state or jurisdiction in which such offer, solicitation or\nsale would be unlawful prior to the registration or qualification under the\nsecurities laws of any such state or jurisdiction. Any offers, solicitations\nof offers to buy, or any sales of securities will be made in accordance with\nthe registration requirements of the Securities Act of 1933, as amended.\n\nAbout Electra Therapeutics\n\nElectra Therapeutics is a late clinical-stage biopharmaceutical company\nfocused on pioneering a new class of precision medicines for the treatment of\nimmune-mediated diseases and cancer. The company’s novel approach targets\nsignal regulatory proteins (SIRP), a family of cell surface receptors whose\nexpression is restricted to specific immune cell populations and increases\nupon activation, to enable selective depletion of disease-driving cells while\npreserving normal immune function. The company’s lead product candidate,\nipsoprubart (ELA026), is a novel pan-SIRP monoclonal antibody currently in a\nglobal registrational program for secondary hemophagocytic lymphohistiocytosis\n(sHLH), a severe hyperinflammatory syndrome for which there are no broadly\napproved therapies and survival has remained consistently poor over the past\ntwo decades. Ipsoprubart is also being evaluated in a Phase 1 clinical trial\nin patients with relapsed/refractory T-cell and natural-killer cell\nmalignancies. ELA822, the company’s second clinical-stage product candidate,\nis a novel SIRPγ-specific antibody being developed for a broad range of\nchronic T cell-mediated immune and inflammatory diseases.\n\nContacts:\n\nInvestor Contact:\nMonique Allaire, THRUST\nmonique@thrustsc.com\n\nMedia Contact:\nSara Sutton, THRUST\nsarah@thrustsc.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/fd8fd901-e478-4b5f-91b6-0bdce351f95f)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-18T00:30:00.144724039Z","server_sent_at_ms":1789691400144},"received_at":"2026-09-18T00:30:00.200Z","source_url":null},"analysis":{"id":"135871","press_release_id":"147039","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["pre-revenue clinical-stage company; IPO proceeds fund a registrational program in an indication with no broadly approved therapies","underwriters' 30-day option for 3,500,000 additional shares (~15% of the base deal) could add further dilution if exercised"],"eventType":"offering","narrative":"Electra Therapeutics priced an upsized initial public offering of 23,333,334 shares at $15.00 per share, with expected gross proceeds of approximately $350.0 million before underwriting discounts and expenses.\n\nShares begin trading on the Nasdaq Global Select Market on September 18, 2026 under the ticker ETRA, with closing expected September 21; underwriters hold a 30-day option to purchase up to 3,500,000 additional shares at the offering price.\n\nJefferies, TD Cowen, Evercore ISI and Cantor are acting as joint book-running managers for the offering.\n\nThe raise funds a late clinical-stage pipeline led by ipsoprubart (ELA026), a pan-SIRP antibody in a global registrational program for secondary hemophagocytic lymphohistiocytosis, plus the second candidate ELA822 in chronic T cell-mediated immune and inflammatory diseases.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Upsized $350M Nasdaq debut hands Electra multi-year runway for its ipsoprubart sHLH registrational program."},"keyFigures":{"dealValueUsd":350000000,"offeringPrice":15,"sharesOffered":23333334,"customDimensions":{"exchange":"Nasdaq Global Select Market","expected_closing_date":"September 21, 2026","expected_trading_date":"September 18, 2026","over_allotment_shares":3500000,"over_allotment_option_days":30}},"namedEntities":{"people":[],"products":["ipsoprubart (ELA026)","ELA822"],"companies":[{"name":"Electra Therapeutics, Inc.","ticker":"ETRA","relationship":"filer/issuer"},{"name":"Jefferies","relationship":"joint book-running manager (underwriter)"},{"name":"TD Cowen","relationship":"joint book-running manager (underwriter)"},{"name":"Evercore ISI","relationship":"joint book-running manager (underwriter)"},{"name":"Cantor","relationship":"joint book-running manager (underwriter)"},{"name":"THRUST","relationship":"investor/media relations agency"}],"dollarAmounts":[{"amount":"$350.0 million","context":"expected gross proceeds before underwriting discounts and offering expenses"},{"amount":"$15.00","context":"price to the public per share"}]},"materialImpact":{"score":3,"reasoning":"Upsized $350.0 million IPO at $15.00 per share is a major capital infusion for a late clinical-stage biotech, materially extending runway for the ipsoprubart registrational program. It is a capital-markets financing event, not an M&A or FDA binary, so it lands below the top rubric tier."},"tickerRelevance":{"others":[],"primary":"ETRA"},"globalImportance":32,"audienceRelevance":22,"eventTypeSecondary":["dilution"],"importanceComponents":{"dealSize":"$350.0 million gross","tickerTier":"small/mid-cap biotech (new listing)","eventGravity":"upsized $350M IPO pricing","sectorWeight":"biotech capital markets event","issuerAuthored":true,"householdBrandBoost":0}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bullish","material_impact_score":3,"narrative":"Electra Therapeutics priced an upsized initial public offering of 23,333,334 shares at $15.00 per share, with expected gross proceeds of approximately $350.0 million before underwriting discounts and expenses.\n\nShares begin trading on the Nasdaq Global Select Market on September 18, 2026 under the ticker ETRA, with closing expected September 21; underwriters hold a 30-day option to purchase up to 3,500,000 additional shares at the offering price.\n\nJefferies, TD Cowen, Evercore ISI and Cantor are acting as joint book-running managers for the offering.\n\nThe raise funds a late clinical-stage pipeline led by ipsoprubart (ELA026), a pan-SIRP antibody in a global registrational program for secondary hemophagocytic lymphohistiocytosis, plus the second candidate ELA822 in chronic T cell-mediated immune and inflammatory diseases.","key_figures":{"dealValueUsd":350000000,"offeringPrice":15,"sharesOffered":23333334,"customDimensions":{"exchange":"Nasdaq Global Select Market","expected_closing_date":"September 21, 2026","expected_trading_date":"September 18, 2026","over_allotment_shares":3500000,"over_allotment_option_days":30}},"named_entities":{"people":[],"products":["ipsoprubart (ELA026)","ELA822"],"companies":[{"name":"Electra Therapeutics, Inc.","ticker":"ETRA","relationship":"filer/issuer"},{"name":"Jefferies","relationship":"joint book-running manager (underwriter)"},{"name":"TD Cowen","relationship":"joint book-running manager (underwriter)"},{"name":"Evercore ISI","relationship":"joint book-running manager (underwriter)"},{"name":"Cantor","relationship":"joint book-running manager (underwriter)"},{"name":"THRUST","relationship":"investor/media relations agency"}],"dollarAmounts":[{"amount":"$350.0 million","context":"expected gross proceeds before underwriting discounts and offering expenses"},{"amount":"$15.00","context":"price to the public per share"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-18T00:30:46.907Z","global_importance":32,"audience_relevance":22,"importance_components":{"dealSize":"$350.0 million gross","tickerTier":"small/mid-cap biotech (new listing)","eventGravity":"upsized $350M IPO pricing","sectorWeight":"biotech capital markets event","issuerAuthored":true,"householdBrandBoost":0}},"durationMs":46696,"modelName":"glm-5.3-flash"}}